"Propanolamines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives.
| Descriptor ID |
D011412
|
| MeSH Number(s) |
D02.033.100.624 D02.033.755.624 D02.092.063.624
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Propanolamines".
Below are MeSH descriptors whose meaning is more specific than "Propanolamines".
This graph shows the total number of publications written about "Propanolamines" by people in this website by year, and whether "Propanolamines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Propanolamines" by people in Profiles.
-
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 08; 14(8):e009591.
-
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
-
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 05; 199:51-58.
-
Multiple sphingolipid abnormalities following cerebral microendothelial hypoxia. J Neurochem. 2014 Nov; 131(4):530-40.
-
New-onset atrial fibrillation predicts heart failure progression. Am J Med. 2014 Oct; 127(10):963-71.
-
YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock. Am J Respir Crit Care Med. 2014 May 01; 189(9):1138-40.
-
Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug; 1(4):338-344.
-
Letter by Rosner et al regarding article, "When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure". Circulation. 2013 Jan 29; 127(4):e431.
-
Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb; 6(1):137-43.
-
Effect of ß-blocker cessation on chronotropic incompetence and exercise tolerance in patients with advanced heart failure. Circ Heart Fail. 2012 Sep 01; 5(5):560-5.